Table 3 Statistically significant effects for outcomes for which the data provided evidence (proof, indication or hint) of greater or lesser benefit of ST compared with CBT (from [9])

I: Affective disorders

 No.1

Depressive symptoms

Beck Depression

Inventory < 9

Week

12 – 16

OR

0.35

[0.13; 0.97]

0.045

Brent et al. [40,41,42,43,44,45,46,47,48,49,50,51,52,53]

▼

V: Mental and behavioural disorders due to psychoactive substance use

 No. 22

Cannabis use disorder

Categories: remission, abuse, dependence

(ADI-Light for cannabis)

Month 12

OR

1.68

[1.15; 2.44]

0.007

INCANT [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]

▲

 No. 25

Symptoms of cannabis use disorder

Number of symptoms of cannabis use disorder (ADI-Light for cannabis)

Month

0 – 12

Cohen’s d

1.27

[0.51; 2.03]

 < 0.001

INCANT [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]

▲

Month 12

MD

 − 0.60

[− 0.99; − 0.21]

0.003

INCANT [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]

 No. 29

Use of cannabis

Days of cannabis use days in the past 90 days, adolescent self-report (TLFB)

Month 12

MD

 − 27.14

[− 44.24; − 10.04]

0.002

Waldron et al. [122, 123]

▲

Month 6

MD

7.90

[− 14.45; − 1.35]

0,018

INCANT [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]

▲

Month 6 / 7

MD

 − 8.22

[− 14.40; − 2.03]

0.009

Meta-analysis:

INCANT [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]

Waldron et al. [122, 123]

▲

Month 12

MD

 − 8.30

[− 14.83; − 1.77]

0.013

INCANT [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]

▲

% of cannabis use days in the past 90 days, adolescent self-report (FORM 90D, TLFB)

Month 4

n/a

n/a

n/a

 < 0.025

Waldron et al. [122, 123]

▲